pragma.vision Your technology observatory

Verification register Bio, Health & Neuro

Readiness verdict

Dyne Therapeutics Zeleciment Rostudirsen (z-Rostudirsen / DYNE-251) — FDA-Accepted Exon-51-Skipping DMD Therapy

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-07-21
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Ready

Primary summary from verified readiness

Confidence
72% · fresh
Computed at
2026-07-21T20:38:48.207486+00:00
Claimed
80

Public ambition and stated capability

Reported
79

Observed practitioner reporting

Verified
73

Independently supported evidence

Gap
+7

Claimed leads verified

Evidence strength Critical

Decision

What the current evidence supports

Human editorial judgment · 2026-07-21

Track; not yet

Why
FDA has only accepted the BLA for review (not approved); the accelerated-approval pathway rests on an unconfirmed surrogate endpoint with no prior exon-skipping ASO in this class having completed a confirmatory trial, so clinical benefit remains unproven pending the ongoing FORZETTO Phase 3.
Next
Re-check at PDUFA action (2027-01-21) for FDA approval decision and any released DELIVER trial numeric efficacy/safety data; escalate to 'Adopt with guardrails' framing only after accelerated approval is granted and functional-endpoint data are public.

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
6
Tier 1
0
Tier 2
5
Tier 3
1
Supports
3
Contradicts
1
Context
2
Latest observed
2026-07-20

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-07-21 Reading moved from ready to ready.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.